Guoyuan Securities released a research report on April 25 stating that it gave Maipu Medical (301033.SZ) a purchase rating. The main reasons for the rating include: 1) rapid penetration of the craniomaxillofacial product group, accelerated release of new medical gel products; 2) active participation in collection, rapid channel expansion, and impressive international growth. (Mainichi Keizai Shimbun)
国元证券4月25日发布研报称，给予迈普医学（301033.SZ）买入评级。评级理由主要包括：1）颅颌面产品群快速渗透，止血纱医用胶新品加速放量；2）积极参与集采，渠道快速拓展，国际化增长亮眼。（每日经济新闻）
Guoyuan Securities released a research report on April 25 stating that it gave Maipu Medical (301033.SZ) a purchase rating. The main reasons for the rating include: 1) rapid penetration of the craniomaxillofacial product group, accelerated release of new
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated